An increasing number of people infected with the hepatitis C virus are being denied a lifesaving treatment by their insurance provider, according to research presented at the 2017 Digestive Disease Week (poster Sa1501).
Trio Health, which has collected real-world data on HCV patients since the launch of the direct-acting antiviral agents (DAAs) in late 2013, said that early on, Medicaid restrictions were the primary driver behind “nonstarts”—people who did not begin therapy